Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Dignify Therapeutics

Explore full profile

Drug therapies for on-demand bladder and bowel control.

Raleigh, United StatesFounded 2013Biotech & Life Sciences
Valuation $10–25M Last recorded · 2015
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Dignify Therapeutics and the history behind them.

About Dignify Therapeutics

Dignify Therapeutics is a drug development company that focuses on creating new drug therapies for bladder and bowel disorders. The company's primary focus is on patients with spinal cord injuries, multiple sclerosis, and other neurological conditions who have lost voluntary control of these functions.

The company's business model revolves around the research and development of pharmaceutical agents. They aim to create products that can be administered on-demand to provide safe and effective bladder and bowel control. This approach addresses a significant unmet need in the market, as current solutions are often inadequate or have significant side effects. Dignify Therapeutics operates in the pharmaceutical and biotechnology sectors, targeting a niche market of patients with neurological-related bladder and bowel dysfunction. The company generates revenue through a combination of research grants, venture capital funding, and future licensing or commercialization of its developed drugs.

By developing novel therapies, Dignify Therapeutics seeks to improve the quality of life for its target patient population, offering them greater independence and dignity. The company has a portfolio of patents and is actively engaged in the drug development process, from preclinical studies to potential clinical trials.

Source: Dealroom company data

At a glance

Founded
2013
Headquarters
Raleigh, United States
Sector
Biotech & Life Sciences

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Aging

Series A2 investors entered at this stage

Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Dignify Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dignify Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.